Wyniki wyszukiwania - Biblioteka Nauki

1

Studies on diversification and restriction of immune response against glycopeptide antigens

100%

Czerwinski M.

Postępy Higieny i Medycyny Doświadczalnej

|

1995

|

tom 49

|

nr 1

23-31

2

Molecular characterization of the monoclonal antibodies recognizing human glycophorin A

100%

Czerwinski M.

Postępy Higieny i Medycyny Doświadczalnej

|

2002

|

tom 56

|

nr 4

461-483

EN

Glycophorin A, the major sialoglycoprotein of human erythrocytes and carrier of MN blood group antigens, is a good model to study immune response against glycopeptide antigens. Molecular analysis of several monoclonal antibodies recognizing GPA revealed that the immune response against N, but not M, antigen is restricted. It was shown that the recombinant Fab fragments expressed in the phage display system may provide novel reagents with application in immunohematology. The new recombinant Fab fragments revealed increased affinity toward GPA. Introduction of dimer-inducing peptides causes creation of bivalent Fab fragments revealing increased avidity.

3

The application of monoclonal antibodies and polymerase chain reaction of DNA to veterinary diagnosis

80%

Markowska-Daniel I. , Pejsak Z. , Stadejek T.

Biotechnologia

|

1995

|

nr 3

44-53

EN

Application of new techniques such as monoclonal antibodies (MAbs) and polymerase chain reaction (PCR) to veterinary diagnosis are persented.

4

Human antibody expression in transgenic mice

80%

Bruggemann M.

Archivum Immunologiae et Therapiae Experimentalis

|

2001

|

tom 49

|

nr 3

203-208

EN

Human antibody repertoires can be created in transgenic mice following the introduction of human immunoglobulin heavy and light chain genes in their germline configuration. Transgene constructs or transloci have been obtained by plasmid assembly, cloning in yeast artificial chromosomes, and the use of chromosome fragments. Translocus integration and maintenance in transgenic mouse strains has been achieved by pronuclear DNA injection into oocytes and various transfection methods using embryonic stem cells. The human DNA segments rearrange faithfully in the mouse and produce extensive V(D)J combinations. Specific human monoclonal antibodies of high affinity for use in therapeutic applications have been produced from these translocus mice.

5

Magic bullets ? monoclonal antibodies in acute leukaemias and non-Hodgkin lymphomas treatment

80%

Luczynski W. , Krawczuk-Rybak M.

Postępy Higieny i Medycyny Doświadczalnej

|

2002

|

tom 56

|

nr 6

789-801

EN

Because of high percent of failures in haematologic malignancies treatment there is a need of discovering new drugs. One of the new approaches are monoclonal antibodies, which target specific cluster differentiation antigens on tumor cells. Rituximab is an anti-CD20 antibody used in non-Hodgkin lymphoma, alemtuzumab - in B chronic lymphocytic leukaemia, gemtuzumab ozogamicin ? in non-lymphoblastic leukaemia, tositumomab and ibritumomab are monoclonal antibodies binded with radiopharmaceutics and are used in non-Hodgkin lymphomas.

6

Monoclonal and bispecific antibodies as novel therapeutics

80%

Booy E. P. , Johar D. , Maddika S. , Pirzada H. , Sahib M. M. , Gehrke I. , Loewen S. , Louis S. F. , Kadkhoda K. , Mowat M. , Los M.

Archivum Immunologiae et Therapiae Experimentalis

|

2006

|

tom 54

|

nr 2

85-101

EN

Gene amplification, over-expression, and mutation of growth factors, or the receptors themselves, causes increased signaling through receptor kinases, which has been implicated in many human cancers and is associated with poor prognosis. Tumor growth has been shown to be decreased by interrupting this process of extensive growth factor-mediated signaling by directly targeting either the surface receptor or the ligand and thereby preventing cell survival and promoting apoptosis. Monoclonal antibodies have long been eyed as a potential new class of therapeutics targeting cancer and other diseases. Antibody-based therapy initially entered clinical practice when trastuzumab/Herceptin became the first clinically approved drug against an oncogene product as a well-established blocking reagent for tumors with hyperactivity of epidermal growth factor signaling pathways. In the first part of this review we explain basic terms related to the development of antibody-based drugs, give a brief historic perspective of the field, and also touch on topics such as the 'humanization of antibodies' or creation of hybrid antibodies. The second part of the review gives an overview of the clinical usage of bispecific antibodies and antibodies 'armed' with cytotoxic agents or enzymes. Further within this section, cancer-specific, site-specific, or signaling pathway-specific therapies are discussed in detail. Among other antibody-based therapeutic products, we discuss: Avastin (bevacizumab), CG76030, Theragyn (pemtumomab), daclizumab (Zenapax), TriAb, MDX-210, Herceptin (trastuzumab), panitumumab (ABX-EGF), mastuzimab (EMD-72000), Erbitux (certuximab, IMC225), Panorex (edrecolomab), STI571, CeaVac, Campath (alemtuizumab), Mylotarg (gemtuzumab, ozogamicin), and many others. The end of the review deliberates upon potential problems associated with cancer immunotherapy.

7

The application of monoclonal antibodies to medical treatment

80%

Kurpisz M.

Biotechnologia

|

1993

|

nr 2

105-120

EN

In this review contemporary trends in the application of monoclonal antibodies are presented. There is discussed antibody reengineering for humanization of mouse monoclonal antibodies to avoid anti-globulin reaction of patient. Recent modifications of antibody fragments are also outlined. The most common antigenic structures exposed to antibody attack are characterized. Some aspects of human monoclonal antibody production are briefly described. Three most promising therapeutic antibodies - bispecific antibodies, immunotoxins, and radiolabeled immunoconjugates - are presented.

8

A mouse monoclonal antibody to the TSHR

80%

Stankowiak-Kulpa H. , Sanders J. , Depraetere H. , Jeffreys J. , Evans M. , Richards T. , Furmaniak J. , Smith B. R.

Archivum Immunologiae et Therapiae Experimentalis

|

2005

|

tom 53

|

nr 4

345-351

EN

Mouse monoclonal antibodies (mAbs) with the ability to inhibit thyrotropin (TSH) binding to the TSH receptor (TSHR) are useful tools to study TSH-TSHR interaction. The 3C3 mAb we produced was found to inhibit binding of TSH to human (h)TSHR but not to porcine (p)TSHR. Purified 3C3 immunoglobulin G (IgG) and its antibody-binding framgnet were prepared using standard methods and their ability to inhibit TSH binding to hTSHR or pTSHR was analyzed using a coated tube assay. The TSHR epitope reactive with 3C3 IgG was determined using Western blotting, ELISA based on peptides corresponding to the TSHR sequence, and the SPOT synthesis technique. RNA was isolated from 3C3 hybridoma cells and the mAb variable (V) region genes were sequenced and analyzed. 3C3 mAb had a 1x108 l/mol binding affinity to the hTSHR as assessed by Scatchard analysis. 3C3 reacted with the hTSHR region between amino acids (aa) 212-230, and two aa differences were found between the corresponding regions in the hTSHR and pTSHR. The light chain (LC) genes of 3C3 were derived from the Vk21 germ line (97.6% homology) and Jk2 genes. The heavy chain (HC) genes were from the V130 germ line (94.6% homology) combined with a D gene (not identified) and JH3 gene. The replacement/silent mutation ratios of 6.0 and 6.5 for the LC and the HC V regions, respectively, indicated that 3C3 underwent antigen-driven maturation. Mouse mAbs of this type should be useful in studying the interactions between the TSHR, TSH, and mAbs in more detail.

9

Immunotherapy in the management of sepsis

70%

Sikora J. P.

Archivum Immunologiae et Therapiae Experimentalis

|

2002

|

tom 50

|

nr 5

317-324

EN

The work presents the role of Gram-negative bacteria endotoxins, pro- and anti-inflammatory cytokines and reactive oxygen species (ROS) in the complex and not fully explained pathogenesis of sepsis. The so called ?respiratory burst? of neutrophils and antioxidant mechanisms of the host are also discussed. The work has focused on possible approaches to the management of sepsis connected with immunotherapy. Neutralisation of endotoxin lypopolysaccharide (LPS), anti-TNF-alpha therapy with monoclonal antibodies or pentoxifylline (PTXF) as well as soluble recombinant cytokine agonists and antagonists used in clinical trials were taken into consideration. Besides, cytokine manipulation therapy, anti-adhesion techniques or glicocorticoides and antioxidant barrier interference were also described. So far there has been no immunotherapy of sepsis in children of proven clinical efficacy, which prompts aggressive examination of the immune system, aimed at affecting its function.

10

Monoclonal antibodies against isoprenoid compounds

70%

Wanke M. , Porebska P. A. , Porebska A. , Walajtys-Rode W.-R. E. , Walajtys-Rode E.

Biotechnologia

|

2001

|

nr 3

169-177

EN

Monoclonal antibodies against isoprenoid compounds were obtained by in vivo immunization of Balb/c mice with UQ-10 (ubiquinone-10) incorporated into cholesterol rich particles containing metylated bovine serum albumin (CRP-MBSA) in order to induce a strong immune response. The specificity of antibodies was evaluated by a modified dot-blot technique using Hybond-N+ membrane (Amersham). Selected antibodies III-5 (IgG3), IV-3 (IgG2b) and VII-11 (IgM) were capable of recognizing different isoprenoid compounds: ubiquinone, plastoquinone, solanesol, dolichol, -sistosterol but did not react with phospholipids, triacylglycerols or fatty acids. These antibodies may be used in immunoblotting for identifying isoprenoids (e.g. ubiquinone) in partially purified plant extracts after TLC chromatography on plastic RP-18 plates (Merck). Immunodetection of isoprenoids was performed using secondary goat anti-mice immunoglobin antibodies conjugated with biotin, extravidine-AP and BCIP/NBT as substrate